Physician profile
Patrick A Golden
NPI 1609890573
$8,080.01
in general payments reported to CMS, 2019-2025
49 companies · $900 in 2025
The $900 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,371 · 2020: $876 · 2021: $1,628 · 2022: $1,285 · 2023: $1,160 · 2024: $860 · 2025: $900.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,920.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,920.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,120.97 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $665.00 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $654.32 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $503.50 | 2019-2024 | Eliquis |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $440.22 | 2021-2025 | Xifaxan, Trulance |
| Janssen Pharmaceuticals, INC | $433.02 | 2019-2022 | |
| Antares Pharma, INC. | $432.74 | 2019-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $420.82 | 2019-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.49 | 2019-2025 | Jardiance |
| Novo Nordisk INC | $368.60 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $268.77 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $268.57 | 2021-2025 | |
| Pfizer INC. | $251.73 | 2019-2025 | |
| Amgen INC. | $156.75 | 2022-2023 | Evenity, Prolia |
| Novartis Pharmaceuticals Corporation | $150.26 | 2019-2022 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Patrick Golden listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.